Luke Walker

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

Antonio Jimeno, Keisuke Shirai, Minsig Choi et al. · Annals of Oncology · 2014 · 99 citations · Full text

Medicine, Oncology, Pharmacology +12

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

Antonio Jimeno, Julie E. Bauman, Charles Weissman et al. · Oral Oncology · 2015 · 78 citations · Full text

Medicine, Oncology, Pharmacology +11

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

Daniel W. Bowles, W W, Neil Senzer et al. · British Journal of Cancer · 2013 · 61 citations · Full text

Medicine, Oncology, Pharmacology +17

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

Benjamin Levy, Alexander I. Spira, Daniel Becker et al. · Journal of Thoracic Oncology · 2014 · 52 citations · Full text

Medicine, Oncology, Pharmacology +14